Genetic variants of the protein kinase C-β1 gene and development of end-stage renal disease in patients with type 2 diabetes

JAMA

Volumn 304, Issue 8, 2010, Pages 881-889

  Ma, Ronald C W ^a   Tam, Claudia H T ^a   Wang, Ying ^a   Luk, Andrea O ^a   Hu, Cheng ^b   Yang, Xilin ^a   Lam, Vincent ^a   Chan, Alfred W H ^a   Ho, Janice S K ^a   Chow, Chun Chung ^a   Tong, Peter C Y ^a   Jia, Weiping ^b   Ng, Maggie C Y ^a,c   So, Wing Yee ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 1; UNCLASSIFIED DRUG; PROTEIN KINASE C;

ADULT; ALLELE; ARTICLE; CHINESE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CHINA; CHRONIC KIDNEY FAILURE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK;

ADULT; AGED; ALLELES; CHINA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEIN KINASE C; RISK;

EID: 77955952739     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1191     Document Type: Article

References (60)

1. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375(9712):408-418.
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia. JAMA. 2009;301(20):2129-2140.
3. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681-1688. (Pubitemid 46048556)
4. Yang W, Lu J, Weng J, et al; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-1101.
5. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes. Am J Kidney Dis. 1999;34(5):795-808.
6. Yang X, So WY, Tong PC, et al; Hong Kong Diabetes Registry. Development and validation of an allcause mortality risk score in type 2 diabetes. Arch Intern Med. 2008;168(5):451-457. (Pubitemid 351547208)
7. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients. Diabetologia. 2005;48(1):17-26.
8. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S14-S21. (Pubitemid 32844108)
9. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519-2527. (Pubitemid 34517197)
10. Yang XL, So WY, Kong AP, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes. Diabetologia. 2006;49(10):2299-2308.
11. Yang XL, So WY, Kong AP, et al. Modified endstage renal disease risk score for Chinese type 2 diabetic patients. Diabetologia. 2007;50(6):1348-1350.
12. Soldatos G, Cooper ME. Diabetic nephropathy. Diabetes Res Clin Pract. 2008;82(suppl 1):S75-S79.
13. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306-1316.
14. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20):2579-2588.
15. He Z, Ma RC, King GL. Role of protein kinase C isoforms in diabetic vascular dysfunction. In: Marso SP, Stern DM, eds. Diabetes and Cardiovascular Disease. Philadelphia, PA: LippincottWilliams & Wilkins; 2004:37-54.
16. Ma RC, Isshiki K, King GL. Protein kinase C and diabetic nephropathy. In: Morgensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. 6th ed. Boston, MA: Kluver Academic Press; 2004.
17. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007;(106):S49-S53. (Pubitemid 47172561)
18. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272(5262):728-731. (Pubitemid 26000279)
19. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100(1):115-126. (Pubitemid 27311249)
20. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14(3):439-447. (Pubitemid 30143162)
21. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbetanull mice. Diabetes. 2006;55(11):3112-3120. (Pubitemid 44923650)
22. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28(11):2686-2690. (Pubitemid 43951160)
23. Araki S, Ng DP, Krolewski B, et al. Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus. J Am Soc Nephrol. 2003;14(8):2015-2024. (Pubitemid 36909909)
24. Araki S, Haneda M, Sugimoto T, et al. Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria. Diabetes Care. 2006;29(4):864-868. (Pubitemid 44115308)
25. Ng MC, Park KS, Oh B, et al. Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes. 2008;57(8):2226-2233.
26. Luk AO, So WY, Ma RC, et al; Hong Kong Diabetes Registry. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes. Diabetes Care. 2008;31(12):2357-2361.
27. Yang X, So WY, Kong AP, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes. Diabetes Care. 2007;30(1):65-70. (Pubitemid 46701550)
28. Hu C, Wang C, Zhang R, et al. Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population. Diabetologia. 2010;53(2):290-298.
29. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937-2944.
30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview. Bioinformatics. 2005;21(2):263-265.
31. Purcell S, Neale B, Todd-Brown K, et al. PLINK. Am J Hum Genet. 2007;81(3):559-575.
32. Sabo PJ, Hawrylycz M, Wallace JC, et al. Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc Natl Acad Sci U S A. 2004;101(48):16837-16842.
33. Robertson G, Bilenky M, Lin K, et al. cisRED. Nucleic Acids Res. 2006;34(Database issue):D68-D73.
34. Ferretti V, Poitras C, Bergeron D, Coulombe B, Robert F, Blanchette M. PReMod. Nucleic Acids Res. 2007;35(Database issue):D122-D126.
35. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445(7130):881-885.
36. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator. Bioinformatics. 2003;19(1):149-150.
37. Toyoda M, Suzuki D, Honma M, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66(3):1107-1114.
38. Langham RG, Kelly DJ, Gow RM, et al. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy. Diabetologia. 2008;51(4):668-674.
39. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273-3277.
40. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195-200.
41. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes. Diabetologia. 2008;51(8):1347-1355.
42. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1569-1576.
43. Kelly DJ, Edgley AJ, Zhang Y, et al. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrol Dial Transplant. 2009;24(6):1782-1790.
44. Chan JC, So WY, Yeung CY, et al; SURE Study Group. Effects of structured versus usual care on renal endpoint in type 2 diabetes. Diabetes Care. 2009;32(6):977-982.
45. Song XY, Lee SY, Ma RC, et al. Phenotype-genotype interactions on renal function in type 2 diabetes. Diabetologia. 2009;52(8):1543-1553.
46. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury. Am J Nephrol. 2006;26(3):232-244.
47. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57(6):1446-1454.
48. Etoh T, Inoguchi T, Kakimoto M, et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia. 2003;46(10):1428-1437.
49. Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005;67(5):1890-1898.
50. Gorin Y, Block K, Hernandez J, et al. Nox4 NAD (P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem. 2005;280(47):39616-39626.
51. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes. Cardiovasc Res. 2009;82(1):9-20.
52. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41:712-717.
53. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376-384.
54. Chambers JC, Zhao J, Terracciano CM, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42(2):149-152.
55. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-116.
56. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(suppl 1):S144-S150.
57. Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007;30(4):995-996.
58. Tuttle KR, Bastyr EJ, McGill JB, Cheng CL, Anderson PW. Albuminuria and kidney function in a long-term study of ruboxistaurin for diabetic nephropathy. J Am Soc Nephrol. 2007;18:48A.
59. Tuttle KR. Protein kinase C-beta inhibition for diabetic kidney disease. Diabetes Res Clin Pract. 2008;82(suppl 1):S70-S74.
60. Parving HH, de Zeeuw D, Cooper ME, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. JAmSoc Nephrol. 2008;19(4):771-779.